CLEARSIDE BIOMEDICAL INC

ABBV-RGX-314 shows 97% reduction in treatment burden at nine months, with zero cases of intraocular inflammation and potential for bilateral wet AMD treatment.

Clearside Biomedical's ODYSSEY Phase 2b trial of CLS-AX for wet AMD achieved primary and secondary outcomes, showing stable best corrected visual acuity (BCVA) and ocular anatomy up to 6 months. CLS-AX, a suprachoroidal injection of axitinib, demonstrated a well-tolerated safety profile and potential for prolonged duration and targeted delivery, reducing injection frequency significantly.